DxGen

Gunpo, South Korea Founded: 2016 • Age: 10 yrs
Point-of-care diagnostic products for diabetes and tuberculosis are provided.

About DxGen

DxGen is a company based in Gunpo (South Korea) founded in 2016. DxGen offers products and services including Epithod® 616 Analyzer, HbA1c Test Kit, CRP Test Kit, AUTODX, and MINI BIOSCIENCE. DxGen operates in a competitive market with competitors including SD Biosensor, Access Bio, Lumos Diagnostics, 1Drop Diagnostics and Fluxergy, among others.

  • Headquarter Gunpo, South Korea
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Website dxgenco.com
  • Legal Name (주)딕스젠 Dxgen Corp

Products & Services of DxGen

DxGen offers a comprehensive portfolio of products and services, including Epithod® 616 Analyzer, HbA1c Test Kit, CRP Test Kit, AUTODX, and MINI BIOSCIENCE.

Epithod® 616 Analyzer
Diagnostic System

Reliable system for diabetes and infectious disease testing.

HbA1c Test Kit
Test Kit

Determines Glycated Hemoglobin levels in human blood.

CRP Test Kit
Test Kit

Measures C-reactive protein in blood for diagnostics.

AUTODX
Diagnostic Platform

System for HbA1c and other biomarker testing.

MINI BIOSCIENCE
Bioscience Tool

Provides tools for biomarker analysis and diagnostics.

Competitors of DxGen

DxGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SD Biosensor, Access Bio, Lumos Diagnostics, 1Drop Diagnostics and Fluxergy, among others.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
sdbiosensor.com2001Suwon-si, South Korea––
Biosensors for point-of-care diagnostics are developed by SD Biosensor.
accessbio.net2001Somerset, United States$22M52
In vitro rapid diagnostic tests, biosensor, and molecular diagnostic products for diagnosis of infectious diseases.
lumosdiagnostics.com2017Carlsbad, United States$40M–
Diversified diagnostic assays and readers are developed for point-of-care use.
1dropdx.com2012Neuchatel, Switzerland$7.75M–
Finger-prick point-of-care diagnostics are provided for biomarker testing.
fluxergy.com2011Irvine, United States–74
Provides diagnostic devices and software for clinical and veterinary point-of-care testing.
diabetomics.com2008Hillsboro, United States$11M35
Point-of-care tests for diabetes and women's health risks are developed.
moduleinnovations.com2014Pune, India$799,890–
Diagnostics strip for bacterial detection
ptsdiagnostics.com1992Indianapolis, United States–211
Point-of-care diagnostic instruments are developed for disease testing.
novabiomedical.com1976Waltham, United States––
Developer of advanced blood testing analyzers and meters. This company manufactures and sells a wide variety of analyzers for hospital, point-of-care, blood bank, biotechnology, veterinary, and sports medicine applications. Products include blood gas analyzers, glucose meters, lactate meters, and cell culture analyzers. They also offer contract development and manufacturing services for other medical device companies. The analyzers utilize various measurement technologies, including potentiometric, amperometric, and spectrophotometric methods. The company provides complete technical support and product information globally.
Premium access

Detailed competitors of DxGen

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Dxgen

Premium access

Complete news archive for DxGen

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Similar companies to DxGen

10 companies that operate in the same segment as DxGen (Diabetes), ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of devices for continuous glucose monitoring and manual insulin delivery
2008San Diego, California, United StatesUSD 100.73 MUSD 1.02 B2,650
Wearable glucose monitoring patches are provided for real-time data tracking.
1999San Diego, California, United StatesUSD 52.5 MUSD 4.66 B10,300
Wearable insulin infusion systems are developed for diabetes patients.
2000Boston, Massachusetts, United StatesUSD 120.4 MUSD 2.71 B3,900
Small molecule drugs for various therapeutic areas are developed.
1995United StatesUSD 165 MUSD 49.8 M103
Implantable continuous glucose monitoring systems are provided for diabetes management.
1996Germantown, United StatesUSD 175.46 MUSD 22.47 M117
Developer of a closed-loop automated insulin delivery system
2014Milpitas, California, United StatesUSD 214.51 M–133
Provider of workforce healthcare solutions
2015New York, New York, United StatesUSD 107.87 M–166
Diabetes care and reversal programs are provided to patients.
2021Bengaluru, Karnataka, IndiaUSD 26.7 MUSD 5.07 M677
Provider of smart devices for diabetes management for patients and doctors
2014San Francisco, California, United StatesUSD 245.2 M––
Genetically engineered cell therapies are developed for multiple disorders.
2018Seattle, Washington, United StatesUSD 821 M–194
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about DxGen

DxGen was founded in 2016.

DxGen is headquartered in Gunpo, South Korea. It is registered at Gunpo, Gyeonggi, South Korea.

DxGen was founded in 2016 and operates in the healthcare diagnostics sector. Point-of-care analyzers and test kits are supplied for diabetes management, covering stages from initial assessment to post-diagnosis treatment. Measurements include HbA1c, glycated albumin, CRP, hemoglobin, micro-albumin, and tuberculosis markers. Multi-marker diagnostic devices for diabetes and tuberculosis patients are under development.

DxGen's top competitors include Access Bio, SD Biosensor and Lumos Diagnostics.

DxGen offers Epithod® 616 Analyzer, HbA1c Test Kit, CRP Test Kit, AUTODX, and MINI BIOSCIENCE.

DxGen operates through (주)딕스젠 Dxgen Corp.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available